JP2015518479A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518479A5
JP2015518479A5 JP2015505024A JP2015505024A JP2015518479A5 JP 2015518479 A5 JP2015518479 A5 JP 2015518479A5 JP 2015505024 A JP2015505024 A JP 2015505024A JP 2015505024 A JP2015505024 A JP 2015505024A JP 2015518479 A5 JP2015518479 A5 JP 2015518479A5
Authority
JP
Japan
Prior art keywords
cell
polypeptide
cells
vector
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015505024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518479A (ja
JP6257584B2 (ja
Filing date
Publication date
Priority claimed from GBGB1206559.5A external-priority patent/GB201206559D0/en
Application filed filed Critical
Publication of JP2015518479A publication Critical patent/JP2015518479A/ja
Publication of JP2015518479A5 publication Critical patent/JP2015518479A5/ja
Application granted granted Critical
Publication of JP6257584B2 publication Critical patent/JP6257584B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015505024A 2012-04-13 2013-04-11 養子細胞療法に有用なポリペプチド Active JP6257584B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1206559.5A GB201206559D0 (en) 2012-04-13 2012-04-13 Polypeptide
GB1206559.5 2012-04-13
PCT/GB2013/050935 WO2013153391A1 (en) 2012-04-13 2013-04-11 Polypeptide useful in adoptive cell therapy

Publications (3)

Publication Number Publication Date
JP2015518479A JP2015518479A (ja) 2015-07-02
JP2015518479A5 true JP2015518479A5 (https=) 2016-04-07
JP6257584B2 JP6257584B2 (ja) 2018-01-10

Family

ID=46209048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015505024A Active JP6257584B2 (ja) 2012-04-13 2013-04-11 養子細胞療法に有用なポリペプチド

Country Status (15)

Country Link
US (4) US10925943B2 (https=)
EP (1) EP2836511B1 (https=)
JP (1) JP6257584B2 (https=)
CN (1) CN104379599B (https=)
AU (1) AU2013246648B2 (https=)
CA (1) CA2870233C (https=)
DK (1) DK2836511T3 (https=)
ES (1) ES2654144T3 (https=)
GB (1) GB201206559D0 (https=)
HU (1) HUE036147T2 (https=)
NO (1) NO2836511T3 (https=)
PL (1) PL2836511T3 (https=)
PT (1) PT2836511T (https=)
TR (1) TR201802560T4 (https=)
WO (1) WO2013153391A1 (https=)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
ES3063961T3 (en) 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
CN104849462B (zh) * 2014-02-17 2017-01-25 湖北大学 一种高灵敏度抗cd20单克隆抗体及其应用
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
CA2943008C (en) 2014-03-19 2021-03-30 Cellectis Cd123 specific chimeric antigen receptors for cancer immunotherapy
WO2015166056A1 (en) 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
US10888608B2 (en) * 2014-09-02 2021-01-12 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
SI3194434T1 (sl) * 2014-09-15 2019-11-29 Molmed Spa Himerni antigenski receptorji
ES2869972T3 (es) 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
EP3283520B1 (en) * 2015-04-13 2020-05-06 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
GB201507111D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507115D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
FI3909972T3 (fi) 2015-06-19 2024-05-03 Sebastian Kobold Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä
CA2994746A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
CN117070468A (zh) 2015-10-05 2023-11-17 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
EP3359660B1 (en) 2015-10-05 2019-12-04 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
EA201891641A1 (ru) 2016-01-21 2019-01-31 Пфайзер Инк. Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
NZ750256A (en) 2016-08-03 2026-02-27 Dipersio John F Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
GB201614093D0 (en) 2016-08-17 2016-09-28 Autolus Ltd Vector
SG11201901642XA (en) 2016-08-26 2019-03-28 Baylor College Medicine Constitutively active cytokine receptors for cell therapy
EP3293199B1 (en) * 2016-09-08 2021-01-13 Heinrich-Heine-Universität Düsseldorf Chimeric antigen receptors
CA3035075A1 (en) 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
JP2019535262A (ja) 2016-11-11 2019-12-12 オートラス リミテッド キメラ抗原受容体
WO2018115189A1 (en) 2016-12-21 2018-06-28 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
EP4414380A3 (en) 2017-03-31 2024-12-04 Cellectis SA Universal anti-cd22 chimeric antigen receptor engineered immune cells
EP4029943A1 (en) 2017-05-08 2022-07-20 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
JP7317718B2 (ja) 2017-06-02 2023-07-31 ファイザー・インク Flt3を標的にするキメラ抗原受容体
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
CA3068465A1 (en) 2017-06-30 2019-01-03 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
WO2019020733A1 (en) 2017-07-26 2019-01-31 Cellectis METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR)
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
WO2019060425A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
US20200239544A1 (en) 2017-10-03 2020-07-30 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
PE20211266A1 (es) 2017-10-31 2021-07-19 Allogene Therapeutics Inc Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas
GB201720948D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Plasmid system
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
US20230158070A1 (en) 2018-01-30 2023-05-25 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
KR102780406B1 (ko) 2018-02-01 2025-03-17 화이자 인코포레이티드 Cd70을 표적으로 하는 키메라 항원 수용체
PE20210708A1 (es) 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos
WO2019169290A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
IT201800003464A1 (it) * 2018-03-13 2019-09-13 Ospedale Pediatrico Bambino Gesu Cellule T CAR-CD30 per il trattamento di tumori CD30+
CA3095795A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
SG11202010116PA (en) 2018-04-13 2020-11-27 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020007593A1 (en) 2018-07-02 2020-01-09 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
GB201812474D0 (en) 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
GB201813178D0 (en) 2018-08-13 2018-09-26 Autolus Ltd Cell
CN109265561B (zh) * 2018-09-25 2021-05-25 山东兴瑞生物科技有限公司 抗EGFRvⅢ安全型嵌合抗原受体、其制备方法、利用其修饰的NK细胞及应用
PL3856775T3 (pl) 2018-09-27 2025-06-09 Autolus Limited Chimeryczny receptor antygenowy
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
SG11202105353PA (en) 2018-12-01 2021-06-29 Allogene Therapeutics Inc Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereof
BR112021017365A2 (pt) 2019-03-01 2022-02-01 Allogene Therapeutics Inc Receptores de citocina quiméricos constitutivamente ativos
EP3931208A1 (en) 2019-03-01 2022-01-05 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a pd-1 ectodomain
WO2020180591A1 (en) 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Dll3 targeting chimeric antigen receptors and binding agents
WO2020183131A1 (en) 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
WO2020191378A1 (en) 2019-03-21 2020-09-24 Allogene Therapeutics, Inc. METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY
JP7286796B2 (ja) 2019-04-03 2023-06-05 プレシジョン バイオサイエンシズ,インク. マイクロrna適合shrna(shrnamir)を含む遺伝子改変免疫細胞
WO2020206231A1 (en) 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
GB201904971D0 (en) 2019-04-08 2019-05-22 Autolus Ltd Cell
KR20220004028A (ko) 2019-04-26 2022-01-11 알로젠 테라퓨틱스 인코포레이티드 동종 car t 세포를 제조하는 방법
JP7664180B2 (ja) 2019-04-26 2025-04-17 アロジーン セラピューティクス,インコーポレイテッド リツキシマブ耐性キメラ抗原受容体およびその用途
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質-金属水酸化物錯体およびその方法
EP3769816A1 (en) * 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
EP4004216A1 (en) 2019-07-25 2022-06-01 Precision BioSciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
GB201911187D0 (en) 2019-08-05 2019-09-18 Autolus Ltd Receptor
AU2020333851A1 (en) 2019-08-20 2022-03-31 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
WO2021041806A1 (en) 2019-08-30 2021-03-04 Allogene Therapeutics, Inc. Chimeric cytokine receptors comprising tgf beta binding domains
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
GB201913258D0 (en) 2019-09-13 2019-10-30 Autolus Ltd Antigen-binding domain
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
EP3808766A1 (en) 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
EP4069285A1 (en) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
GB201918908D0 (en) 2019-12-19 2020-02-05 Autolus Ltd Cell
GB201919019D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
US20230060351A1 (en) * 2020-01-08 2023-03-02 Board Of Regents, The University Of Texas System A method of engineering natural killer cells to target cd70-positive tumors
CA3168433A1 (en) 2020-01-16 2021-07-22 Allogene Therapeutics, Inc. Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors
JP2023514407A (ja) 2020-02-24 2023-04-05 アロジーン セラピューティクス,インコーポレイテッド 増強された活性を有するbcma car-t細胞
EP4110823A1 (en) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
KR20240096884A (ko) 2020-03-10 2024-06-26 매사추세츠 인스티튜트 오브 테크놀로지 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
KR102371151B1 (ko) 2020-03-13 2022-03-07 주식회사 큐로셀 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물
JP2023518049A (ja) 2020-03-16 2023-04-27 ユニバーシティ オブ サザン カリフォルニア 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
JP7755597B2 (ja) 2020-04-09 2025-10-16 オートラス リミテッド 細胞
WO2021205175A1 (en) 2020-04-09 2021-10-14 Autolus Limited Molecule
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
GB202007842D0 (en) * 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy
EP4185610A2 (en) 2020-07-21 2023-05-31 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
WO2022035793A1 (en) 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
GB202013477D0 (en) * 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
WO2022076547A1 (en) 2020-10-07 2022-04-14 Precision Biosciences, Inc. Lipid nanoparticle compositions
GB202017343D0 (en) 2020-11-02 2020-12-16 Autolus Ltd Cell
EP4240376B1 (en) 2020-11-09 2026-03-25 Quell Therapeutics Limited Method for cryopreserving engineered tregs
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
WO2022132720A1 (en) 2020-12-14 2022-06-23 Allogene Therapeutics, Inc. Methods and reagents for characterizing car t cells for therapies
GB202019879D0 (en) 2020-12-16 2021-01-27 Ucl Business Ltd Polypeptide
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
WO2022165111A1 (en) 2021-01-28 2022-08-04 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
AU2022212090A1 (en) 2021-01-28 2023-07-06 Allogene Therapeutics, Inc. Methods for transducing immune cells
TW202245811A (zh) 2021-02-03 2022-12-01 美商異基因治療有限公司 用於car t細胞藥物產品的調配物與製程
CA3230245A1 (en) 2021-09-01 2023-03-09 Springworks Therapeutics, Inc. Synthesis of nirogacestat
TW202321286A (zh) 2021-09-21 2023-06-01 英商圭爾醫療有限公司 抗p75ntr嵌合抗原受體
WO2023047100A1 (en) 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-trem2 chimeric antigen receptor
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
US20250009800A1 (en) 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
US20250041417A1 (en) 2021-12-10 2025-02-06 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2023139360A1 (en) 2022-01-19 2023-07-27 Autolus Limited Nucleic acid construct
EP4215245A1 (en) 2022-01-19 2023-07-26 Innovative Cellular Therapeutics Holdings, Ltd. Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment
CN119053618A (zh) * 2022-02-04 2024-11-29 恩基尔特医疗有限公司 嵌合ilt受体组合物和方法
WO2023180690A1 (en) 2022-03-22 2023-09-28 Quell Therapeutics Limited Methods and products for culturing t cells and uses thereof
CA3254552A1 (en) 2022-04-28 2023-11-02 Allogene Therapeutics Inc. METHODS FOR ANALYZING DONOR CELLS
CN119343464A (zh) 2022-06-09 2025-01-21 艾洛基治疗公司 用于检测细胞中基因组异常的方法
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
IL317811A (en) 2022-07-25 2025-02-01 Interius Biotherapeutics Inc Mutated polypeptides, compositions containing them and uses thereof
EP4572774A1 (en) 2022-08-16 2025-06-25 Allogene Therapeutics, Inc. In vitro method for inhibiting hhv-6 infection
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白18﹒2之嵌合抗原受體及結合劑以及其用途
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
GB202219568D0 (en) 2022-12-22 2023-02-08 Autolus Ltd Chimeric antigen receptor
WO2024148167A1 (en) 2023-01-05 2024-07-11 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
KR20250169635A (ko) 2023-01-23 2025-12-03 메디치니쉐 호흐슐레 하노버 항-entpd3 키메라 항원 수용체
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4669343A1 (en) 2023-02-24 2025-12-31 Medizinische Hochschule Hannover CHIMERIC ANTIGEN RECIPIENT
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4683717A1 (en) 2023-03-20 2026-01-28 Autolus Limited A chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma
CN121586582A (zh) 2023-03-20 2026-02-27 汉诺威医学院 嵌合抗原受体
WO2024194649A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t cells and uses thereof
WO2024194642A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t regulatory cell
EP4442322A1 (en) 2023-04-06 2024-10-09 Medizinische Hochschule Hannover Liver-specific car for use against immunologic rejection
WO2024256824A1 (en) 2023-06-14 2024-12-19 Autolus Limited Chimeric antigen receptors directed against trbc1 and trbc2
KR20260025162A (ko) 2023-06-20 2026-02-23 알로젠 테라퓨틱스 인코포레이티드 조작된 세포의 검출 방법
EP4731648A1 (en) 2023-06-21 2026-04-29 Quell Therapeutics Limited Constitutive cytokine receptors
GB202309704D0 (en) 2023-06-27 2023-08-09 Autolus Ltd Chimeric transmembrane protein
WO2025029606A1 (en) * 2023-07-28 2025-02-06 Beam Therapeutics Inc. Modified immune effector cells with improved resistance to natural killer cell-mediated allorejection
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
EP4512415A1 (en) 2023-08-24 2025-02-26 Medizinische Hochschule Hannover Chimeric antigen receptor for treatment of multiple sclerosis or alzheimer's disease
WO2025040799A1 (en) 2023-08-24 2025-02-27 Medizinische Hochschule Hannover Car for treatment of ms or ad
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
GB202405382D0 (en) 2024-04-16 2024-05-29 Ucl Business Ltd Chimeric antigen receptor
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct
EP4678187A1 (en) 2024-07-11 2026-01-14 Medizinische Hochschule Hannover Compound for use in the treatment of inflammatory bowel disease
WO2026027876A1 (en) 2024-07-29 2026-02-05 Quell Therapeutics Limited Chimeric antigen receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US621147A (en) * 1899-03-14 Presser-foot for sewing-machines
DK2124999T3 (da) * 2006-12-18 2013-01-14 Acceleron Pharma Inc Activin-actrii antagonister og anvendelser til behandling af anæmi
JP4345819B2 (ja) 2007-01-19 2009-10-14 トヨタ自動車株式会社 エコドライブ支援装置、エコドライブ支援方法
TWI782836B (zh) * 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor

Similar Documents

Publication Publication Date Title
JP2015518479A5 (https=)
JP7452880B2 (ja) Ssx2抗原を識別するt細胞受容体
TWI908706B (zh) CARTyrin組成物和使用方法
JP7253020B2 (ja) キメラ抗原受容体およびその使用
JP6849600B6 (ja) キメラ抗原受容体、組成物及び方法
JP7048494B2 (ja) 修飾t細胞に対する条件的活性型キメラ抗原受容体
WO2018104407A1 (en) T cell receptors with improved pairing
JP2019528033A (ja) 抗pd−1ナノ抗体およびその使用
KR102316091B1 (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
JP7429455B2 (ja) Afp抗原を識別するt細胞受容体
JP2016538855A5 (https=)
KR20210141573A (ko) 항-bcma 키메라 항원 수용체
JP2025071138A (ja) ナノトランスポゾン組成物および使用方法
CN106188275A (zh) 识别ny-eso-1抗原短肽的t细胞受体
CN106478807B (zh) 识别mage-a3的t细胞受体
KR20220093103A (ko) 항종양용해 바이러스 항원 항체 및 이의 사용 방법
US20240209088A1 (en) Novel single domain antigen binding molecules and their uses
CN115135672A (zh) 抗muc1组合物和使用方法
US20240344030A1 (en) Multiprotein-engineered cells secreting a multispecific antibody
CN106336457B (zh) 识别mage‑a3抗原短肽的t细胞受体
CN106632658B (zh) 识别ny-eso-1抗原短肽的tcr
JP2026041861A (ja) Il2オルソログおよび使用法
CN106478808A (zh) 识别ny-eso-1抗原短肽的t细胞受体
JP2021536256A (ja) 修飾t細胞に対する条件的活性型キメラ抗原受容体
JP7429462B2 (ja) Ssx2抗原の短いペプチドを識別するt細胞受容体